{"version":"1.0","type":"link","title":"First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.","author_name":"Peters S 외","author_url":"https://prs-insight.online/author/Peters%20S","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/93954","thumbnail_width":1200,"thumbnail_height":630}